Curis, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 49
- Market Cap
- $35.9M
- Website
- http://www.curis.com
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01171924
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
🇺🇸Mountain Blue Global Cancer Care, Wheat Ridge, Colorado, United States
🇺🇸San Diego Pacific Oncology and Hematology Associates, Encinitas, California, United States
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00728793
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸START (South Texas Accelerated Research Therapeutics), San Antonio, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath